Is Abbott Laboratories (ABT) a Buy, Sell, or Hold?
Abbott Laboratories
NYSE:ABT
$88.965 USD
-$3.15 (-3.41%)
- Volume
- 12.46M
- Average Volume
- 13.31M
- Market Capitalization
- $154.96B
- P/E Ratio
- 24.71
- Dividend Yield
- 2.79%
- Price Target
- $120.50
- Year High
- $137.49
- Year Low
- $81.97
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.67
- Current Ratio
- $1.39
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Robert Ford |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | ABT |
| CUSIP | 002824100 |
| CIK | 0000001800 |
| Web | https://www.abbott.com |
| Phone | 224 667 6100 |
| Currency | USD |
| Employees | 114000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.65 |
| Payout Ratio | 0.67 |
| Current Ratio | 1.39 |
| Quick Ratio | 1.01 |
| Cash Ratio | 0.37 |
Sales & Book Value
| Annual Sales | $44.33B |
| Price / Sales | 3.43 |
| Cash Flow | 4.22 |
| Price / Cash Flow | 21.00 |
| Price / Book | 2.99 |
Price Target and Rating
| Average Stock Price Forecast | $120.50 |
| High Stock Price Forecast | $145.00 |
| Low Stock Price Forecast | $92.00 |
| Forecast Upside/Downside | -26.17% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 41 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $3.72 |
| Trailing P/E Ratio | 24.71 |
| PEG Ratio | -0.46 |
| P/E Growth | -0.46 |
| Net Income | $6.52B |
| Net Margin | 13.91% |
| Pretax Margin | 18.03% |
| Return on Equity | 12.20% |
| Return on Assets | 5.68% |
Financials Score
| AltmanZ Score | 3.00 |
| Piotroski Score | 6.00 |
| Working Capital | 7.13B |
| Total Assets | 110.43B |
| Ebit | 8.49B |
| Market Cap | 156.14B |
| Total Liabilities | 57.73B |
Poll Results
About Abbott Laboratories (NYSE:ABT) Stock
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, infla ... mmation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?
2026-07-14 10:35:14
ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.
Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
2026-07-13 16:47:09
Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently.
Unlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
2026-07-13 10:15:22
Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Abbott Labs Vs. Danaher: Abbott's Everyday Products Beat Danaher's Slumping Biotech Equipment
2026-07-10 14:18:48
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) and Danaher (NYSE:DHR) both closed the books on Q1 2026 with very different stories.
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet
2026-07-09 10:31:08
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
2026-07-08 17:03:46
Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized focus on disruptive ophthalmic technologies for glaucoma and corneal care.
2026-07-07 17:30:00
Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.
5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years
2026-07-07 14:00:00
Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.
Frequently Asked Questions
-
What is the current Abbott Laboratories (ABT) stock price?
-
Abbott Laboratories(NYSE:ABT) stock price is $88.965 in the last trading session. During the trading session, ABT stock reached the peak price of $137.49 while $81.97 was the lowest point it dropped to. The percentage change in ABT stock occurred in the recent session was --3.41% while the dollar amount for the price change in ABT stock was -$-3.15.
-
ABT's industry and sector of operation?
-
The NYSE listed ABT is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of ABT?
-
Robert Ford | Executive Chairman, President & CEO
Scott Michael Leinenweber | Senior Vice President of Licensing, Acquisitions & Ventures
Mary K. Moreland | Executive Vice President of Human Resources
Michael Comilla | Vice President of Investor Relations.
Sabina Ewing | Senior Vice President of Business & Technology Services and Chief Information Officer -
How many employees does ABT have?
-
Number of ABT employees currently stands at 114000. ABT operates from 100 Abbott Park Road, Abbott Park, IL 60064-6400, US.
-
Link for ABT official website?
-
Official Website of ABT is: https://www.abbott.com
-
How do I contact ABT?
-
ABT could be contacted at phone #224 667 6100 and can also be accessed through its website. ABT operates from 100 Abbott Park Road, Abbott Park, IL 60064-6400, US.
-
How many shares of ABT are traded daily?
-
The average number of ABT shares traded daily for last 3 months was 13.31M.
-
What is the market cap of ABT currently?
-
The market value of ABT currently stands at $154.96B with its latest stock price at $88.965